Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Is there a role for the use of IFN-α in primary myelofibrosis?

Hematology. American Society of Hematology. Education Program - 1 Jan 2012

Nguyen Huong Marie, Kiladjian Jean-Jacques

Abstract excerpt

A 62-year-old man with a history of diabetes and hypertension is referred to your hematology clinic for an incidental discovery of anemia. He does not have any constitutional symptoms and previous blood counts have been within the normal range. He has hepatosplenomegaly with a palpable spleen of 6 cm below the left costal margin and a liver size of 2.5 cm below the right costal margin. Laboratory evaluation shows...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy
Share to Bone Marrow
Share to Bone Marrow Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Hematology

Share to Interferon-alpha

Share to Janus Kinase 2

Share to Primary Myelofibrosis

Source

Identifiers

PMID: 23233636
DOI: 10.1182/asheducation-2012.1.567

Genes

BCR
JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Is there a role for the use of IFN-α in primary myelofibrosis?PMID 23233636Read ↗

Pegylated interferon: the who, why, and howSemantic proximity Read ↗

The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.Semantic proximity Read ↗

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?Semantic proximity Read ↗

Long-acting interferon: pioneering disease modification of myeloproliferative neoplasms.Semantic proximity Read ↗

Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.Semantic proximity Read ↗

Optimizing IFN Alpha Therapy against Myeloproliferative Neoplasms.Semantic proximity Read ↗

Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response.Semantic proximity Read ↗

Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant cloneSemantic proximity Read ↗

The presence of -308A TNFα is associated with anemia and thrombocytopenia in patients with myelodysplastic syndromes.Semantic proximity Read ↗

How do JAK2-inhibitors work in myelofibrosis: an alternative hypothesis.Semantic proximity Read ↗

[Anti-angiogenic effect of interferon on JAK2V617F positive myeloproliferative neoplasms and its anti-angiogenic mechanisms].Semantic proximity Read ↗

Acquired resistance to interferon alpha therapy associated with homozygous MPL-W515L mutation and chromosome 20q deletion in primary myelofibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.